News Sentiment

TARA sentiment intelligence

Protara Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.32 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+6.4% over one week, +10.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

What's Driving Protara's Recent Surge

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 6.4% Price confirming higher
Trend fit Trend inactive 10.8% over four weeks
Fair value 20.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 47
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
TradingView 8
Market source 6
simplywall.st 5
GlobeNewswire 4
MT Newswires 2
TradingKey 2
Kavout | AI 1

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 19
Deals and strategy 2
Analyst action 2
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Stock Titan Direct company coverage

Protara Therapeutics (TARA) investors approve share increase and pay items

Protara Therapeutics, Inc. (TARA) stockholders approved all seven proposals at their recent Annual Meeting, including the election of three Class III directors, the ratification of Ernst & Young LLP as auditor, and advisory approvals for executive compensation and an annual say-o

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Protara Therapeutics (NASDAQ: TARA) CCO has 6,008 RSU shares withheld for taxes

Protara Therapeutics' Chief Commercial Officer, William Conkling, had 6,008 shares withheld by the company to cover income tax obligations related to the vesting of Restricted Stock Unit Awards. This transaction, valued at $4.34 per share, was an administrative tax-withholding di

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:10
Source
Stock Titan
marketscreener.com Direct company coverage

Protara Therapeutics - enters sales agreement with TD Cowen for common stock offering

Protara Therapeutics has entered into a sales agreement with TD Cowen for a common stock offering. This news comes amidst other recent developments for the clinical-stage biotechnology company, including positive updated 12-month data from a Phase 2 trial of its lead candidate, T

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 21:09
Source
marketscreener.com
Stock Titan Direct company coverage

Protara Therapeutics (NASDAQ: TARA) secures $100M ATM sales agreement with TD Cowen

Protara Therapeutics (NASDAQ: TARA) has entered into an at-the-market (ATM) sales agreement with TD Cowen to sell up to $100 million of its common stock. This offering is part of a larger $300 million shelf registration and the proceeds will primarily fund the clinical developmen

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 20:09
Source
Stock Titan